High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. - Wikidata - awgldk - TriplyDB

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

http://www.wikidata.org/entity/Q33806054

about

Modern approaches to HLA-haploidentical blood or marrow transplantation Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients Alternative donor transplant of benign primary hematologic disorders Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation Mesenchymal stem cells: immune evasive, not immune privileged Graft-versus-host disease: why have we not made more progress?The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation Graft-versus-host disease: state of the science.Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide Bone marrow transplantation concurrently reconstitutes donor liver and immune system across host species barrier in mice Novel regulatory therapies for prevention of Graft-versus-host disease.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning Have we made progress in the management of chronic graft-vs-host disease?Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.Progress toward curing HIV infections with hematopoietic stem cell transplantation.How we treat chronic graft-versus-host disease.High-dose cyclophosphamide for graft-versus-host disease prevention.T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease Have we improved in preventing and treating acute graft-versus-host disease?Prevention of graft-vs.-host disease Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

P2860

Q26797506-889C9CDB-5253-4F33-872D-6AC7E35E8E78 Q26799602-E9AAFD36-61EB-4CE7-A77B-74E0D0F2D91E Q26823398-AF506E28-9F76-4D3D-B843-6B80F97DE460 Q26852474-88790DA5-B9AD-4720-B8CA-C9A086993C50 Q27003371-E98ADF3F-663E-4E30-A995-1880F41B2EF2 Q27012940-B1E854DA-44B0-454D-BF69-E2A50DDEEA95 Q28076264-620EECC0-5629-4CB9-9173-7CC5F0C8D6DD Q28080943-3B6902C3-E0CD-44C6-BBCF-E8E300F531FD Q28732371-B67DE3DC-0355-4BA6-ACF4-A238B9DE50FE Q33424486-A573838C-DCD8-4E4B-9E8E-BBAAF0C7DCCE Q33608520-42707107-3C57-44E9-8C8C-DC65F21AF14D Q33724352-CE34FBA8-0A43-4219-9CC7-C4A866739EE6 Q33732489-6E51AD8C-45B4-41C6-B97E-E5B5BE2AFCE4 Q33764825-35075FE3-7763-4F70-B83B-F5BAB5C3AF04 Q33977923-383541E8-8E80-4B5F-B698-5A6318F17296 Q34138598-270DD28D-EB85-4837-806D-41F289D83A5B Q34142453-66359377-4B8E-4BA5-9A50-08F32DC00389 Q34269481-39BF81C7-46E6-4B3E-8219-FD5F13EBAACB Q34293038-76FA9325-A7C4-4DA1-8B84-AB4AFC990EF4 Q34402494-394B19A8-DFE9-4F12-A174-145FD5DE8712 Q34644980-6B9C5ABB-1F02-4C7F-9A10-1E05BB55029F Q34684038-10A22856-9BDD-4CC4-B5CF-C71DE56F0C4C Q34714792-157F5180-8762-4954-9534-C0AF9D89D58C Q34960346-DB3ACE0C-9739-4ABF-BEB2-DA4F94415600 Q34974480-C500F4FD-A01C-447E-ACDA-D10D85D21A75 Q35004923-FC4AE746-F066-4D8E-AEDE-AFD589837599 Q35110765-FFAD9541-F5E0-466F-B109-7D7A8C3276A8 Q35236079-3D8278F2-2C1C-41B1-8A5F-2B159BD95358 Q35583434-B2A1253F-7A24-472A-9553-60D11C6B4482 Q35800856-0E414393-3DB8-4DEC-A0E7-F382DAB6792A Q36203692-3CCC33B4-61D5-49D8-A61D-6D71EB358BA9 Q36431047-F59B9DA9-61DB-40D5-991A-836EF59AF77A Q36445665-C657FEC8-06B9-4454-A5F0-CB992392F786 Q36488985-E5F2F669-61F9-4E5A-A711-AA5981F4D4E6 Q36662079-5892DC42-001F-4484-B8AD-E7F0D1E7B29C Q36700499-459BCBC5-6353-43D0-B0DF-4C3EA796226D Q36703516-D5ABB0DB-1D8A-4ADE-937C-AA9A54FA77D3 Q36752218-7E5AA577-5240-48E6-A181-CB51875208A9 Q36754109-231980A4-42AC-4B04-AEC1-BDDADE7F17BF Q36779819-F9E4E634-05F6-48DD-A47B-2A1C53EC7188

P2860

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

http://www.wikidata.org/entity/Q33806054

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

High-dose cyclophosphamide as ...... of graft-versus-host disease.

@ast

High-dose cyclophosphamide as ...... of graft-versus-host disease.

@en

type

label

High-dose cyclophosphamide as ...... of graft-versus-host disease.

@ast

High-dose cyclophosphamide as ...... of graft-versus-host disease.

@en

prefLabel

High-dose cyclophosphamide as ...... of graft-versus-host disease.

@ast

High-dose cyclophosphamide as ...... of graft-versus-host disease.

@en

P1433

Q33806054-983CC11E-5B91-4A82-8F3A-5E72A003F556

P1476

Q33806054-BE8EBDFA-C94F-4272-9568-A5C3EE25637E

P2093

Q33806054-0774C02E-87E4-473C-9EC3-3F7B0D97C989

Q33806054-274C1383-D474-4128-A4BC-4936710FC157

Q33806054-4E469C30-5DF1-45F2-949A-30A6693B2ECB

Q33806054-53F70E88-CF83-4C4B-A6C3-61313C01EBDF

Q33806054-67ECA3B4-5AFF-4F67-BA02-219B112642D0

Q33806054-68DA373A-1CC2-42E1-87AC-943BE3227AD6

Q33806054-7266322B-7BB4-4C78-9098-51179A79B18C

Q33806054-8279F881-AE84-4831-AD03-A7ABA2F4B086

Q33806054-8DD12D23-92C9-4BBE-9267-BB48CCAAE030

Q33806054-9B017E73-8ED7-4E7D-A250-2D6B3AABA6BA

P2860

Q33806054-05D14FF3-E61A-4F3A-B4DC-25EDBED18AA6

Q33806054-0D5D462C-982B-41E6-B897-B81A4A2D6796

Q33806054-29F1AC81-2F09-4A82-93A5-C318DD3A9802

Q33806054-38B80076-DCAE-446E-986E-5C57DF8C8B89

Q33806054-411A6786-6FB7-4C25-8773-BAFD19CE8AA9

Q33806054-41BBDB91-F64C-4058-BE06-0466FB74101B

Q33806054-4A5FDFB9-8632-4463-A866-540C3B7F2536

Q33806054-50B89211-0C99-49CB-A50D-96C4D5E117A6

Q33806054-5107D5A2-B25E-4EF7-AD65-EFD7306963ED

Q33806054-54E0634B-C9CC-4E05-BD27-8EDC59BBB044

P304

Q33806054-F1FA9F1E-C800-43E3-8E1E-3AB9864243F0

P31

Q33806054-28587A23-890B-4960-938A-910AD023DFC1

P356

Q33806054-E9B1D232-6B47-455A-9CB1-77F8732EBB00

P407

Q33806054-2EBFFF2B-3C85-42DE-A247-B0C4DF4B5FAB

P433

Q33806054-3463FC8B-B111-45A1-BBF4-DFDDC819EE14

P478

Q33806054-326C71B4-051E-4FDA-82BA-C27C00849DF6

P50

Q33806054-D951A08A-9794-426B-B2E8-6C9A3A906A3B

P577

Q33806054-5AB99A0D-B9B9-4E05-AF27-514D38183AD7

P5875

Q33806054-053674D3-AF8D-4CD6-BA5F-FABCBA4917A8

P698

Q33806054-D4018198-E288-4167-878E-5C21461AED29

P932

Q33806054-25C7F6E0-AE15-47FC-A8C9-0FA5A1047897

P356

BLOOD-2009-11-251595

P1433

P1476

High-dose cyclophosphamide as ...... s of graft-versus-host disease

@en

P2093

Allan Hess

http://www.w3.org/2001/XMLSchema#string

Allen R Chen

http://www.w3.org/2001/XMLSchema#string

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Carol Ann Huff

http://www.w3.org/2001/XMLSchema#string

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Hyam I Levitsky

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

Javier Bolaños-Meade

http://www.w3.org/2001/XMLSchema#string

Jonathan D Powell

http://www.w3.org/2001/XMLSchema#string

Leo Luznik

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical aspects of the analysis of data from retrospective studies of disease

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.

Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Aplastic anaemia.

Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

P304

3224-3230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-11-251595

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41399598

http://www.w3.org/2001/XMLSchema#string

P698

20124511

http://www.w3.org/2001/XMLSchema#string

P932

2858487

http://www.w3.org/2001/XMLSchema#string